

track



Treatment of CVD with low dose
Rivaroxaban in Advanced CKD

Track Trial Patient Alert Card

Name: _____

Study Investigator: _____

Phone: _____

Hospital: _____

This person is enrolled in the TRACK study and is taking one of the following study medications twice daily:

Rivaroxaban 2.5mg OR placebo.

Show this card to any health care professional whom you consult. Keep this card with you at all times.

My TRACK Schedule

Study visit

Study visit details

| Study visit | Study visit details |
|-------------|---------------------|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |



The George Institute
for Global Health

INR and aPTT values are not dependable measures of rivaroxaban. If this person requires an invasive procedure or surgery, develops an illness requiring a medication or hospitalisation, or requires anticoagulant or antiplatelet therapy, please contact the study investigator.

Additional information may be found at:

www.tracktrial.org

track 

Treatment of CVD with low dose
Rivaroxaban in Advanced CKD